http://ift.tt/eA8V8J
WESTPORT, Conn.–(BUSINESS WIRE)–PreScience Labs, LLC (“PreScience”) announced today that it has closed on an initial tranche of its first institutional round of financing. The money raised will support the Company’s pursuit of an Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (“FDA”) for evaluation of its new reformulated, systemically delivered anti-cancer drug known as PS-102. Camden Partners is the lead investor of this $2 million Series AA Round. P
April 26, 2017 at 06:59PM
from
No comments:
Post a Comment